The risk of developing a hypoglycemia episode after cohort entry was also higher among NPH insulin initiators The rate of events in the DPP-4 inhibitor group was similar to that found in a pooled analysis of 19 double-blind clinical studies with type 2 diabetes patients taking sitagliptin or comparator agent (placebo or an active comparator) [25]. Here, INS is linked to Hypoglycemia.